64Cu-LLP2A PET Imaging in Diagnosing Patients with Multiple Myeloma

Inclusion Criteria

• Adult patients 18 years of age or older clinically or pathologically defined MM in accordance with International Myeloma Working Group or as stated in office note / clinical assessment from treating physician * All types of active myeloma are eligible including both newly diagnosed and previously treated provided plans are to start a new treatment or restart a prior treatment
• HEALTHY VOLUNTEER SUBJECTS: No known hematologic disorder such as anemia, leukemia, etc. who is considered healthy based on assessment by principal investigator (PI). (Cohort 1 only)
• Able to give informed consent
• Does not have any exclusions related to PET/MR imaging: No implanted medical devices such as: pacemaker, defibrillator, neurostimulator, artificial heart valve, cerebral aneurysm clips, no accidental exposure to metal fragments (if applicable) * If applicable for administration of contrast with MRI imaging subject must have a calculated glomerular filtration rate (GFR) of at least 60 mg/mL/1.73 m^2
• Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative

Exclusion Criteria

• Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 2 years
• Unable to tolerate up to 90 min of PET/MR or PET/CT imaging per imaging session